Scientific consensus on the COVID-19 pandemic: we need to act now

The infection fatality rate of COVID-19 is several-fold higher than that of seasonal influenza,2 and infection can lead to persisting illness, including in young, previously healthy people (ie, long COVID).3 It is unclear how long protective immunity lasts,4 and, like other seasonal coronaviruses, S...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet 2020-10, Vol.396 (10260), p.e71-e72
Main Authors:	Alwan, Nisreen A, Burgess, Rochelle Ann, Ashworth, Simon, Beale, Rupert, Bhadelia, Nahid, Bogaert, Debby, Dowd, Jennifer, Eckerle, Isabella, Goldman, Lynn R, Greenhalgh, Trisha, Gurdasani, Deepti, Hamdy, Adam, Hanage, William P, Hodcroft, Emma B, Hyde, Zoë, Kellam, Paul, Kelly-Irving, Michelle, Krammer, Florian, Lipsitch, Marc, McNally, Alan, McKee, Martin, Nouri, Ali, Pimenta, Dominic, Priesemann, Viola, Rutter, Harry, Silver, Joshua, Sridhar, Devi, Swanton, Charles, Walensky, Rochelle P, Yamey, Gavin, Ziauddeen, Hisham
Format:	Article
Language:	eng
Subjects:	Aerosols Betacoronavirus Bicycles Communicable Disease Control - methods Communicable Disease Control - standards Consensus Coronavirus Infections - prevention & control Coronavirus Infections - transmission Coronaviruses Correspondence COVID-19 Disease transmission Epidemics Europe Evidence-Based Medicine Humans Hygiene Immunity, Herd Infections Influenza Minimal residual disease Monoclonal antibodies Mortality Pandemics Pandemics - prevention & control Pharmaceuticals Pneumonia, Viral - prevention & control Pneumonia, Viral - transmission Population Public health SARS-CoV-2 Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Stock options Vaccines Ventilation Viral diseases Viruses
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The infection fatality rate of COVID-19 is several-fold higher than that of seasonal influenza,2 and infection can lead to persisting illness, including in young, previously healthy people (ie, long COVID).3 It is unclear how long protective immunity lasts,4 and, like other seasonal coronaviruses, SARS-CoV-2 is capable of re-infecting people who have already had the disease, but the frequency of re-infection is unknown.5 Transmission of the virus can be mitigated through physical distancing, use of face coverings, hand and respiratory hygiene, and by avoiding crowds and poorly ventilated spaces. PK reports personal fees from Kymab, outside the submitted work; PK also has a patent ‘Monoclonal antibodies to treat and prevent infection by SARS-CoV-2 (Kymab)’ pending and is a scientific advisor to the Serology Working Group (Public Heath England), Testing Advisory Group (Department of Health and Social Care) and the Vaccines Task force (Department for Business, Energy and Industrial Strategy). CS reports grants from BMS, Ono-Pharmaceuticals, and Archer Dx (collaboration in minimal residual disease sequencing technologies), outside the submitted work; personal fees from Bristol Myers Squibb, Roche-Ventana, Ono Pharmaceutical, GlaxoSmithKline, Novartis, Celgene, Illumina, MSD, Sarah Canon Research Institute, Genentech, Bicycle Therapeutics, and Medicixi, outside the submitted work; personal fees and stock options from GRAIL and Achilles Therapeutics, outside the submitted work; and stock options from Epic Biosciences and Apogen Biotechnologies, outside the submitted work.
ISSN:	0140-6736 1474-547X